Roivant Sciences (ROIV) EBT Margin Growth (3y) (2023 - 2026)

Roivant Sciences (ROIV) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 132.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -674,462.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 8,006.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 71,157.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -5,319.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,980.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 31,363.00
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -1.89 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.89 Mn
Dec 31, 2025 -943,642.00
Sep 30, 2025 -762,030.00
Jun 30, 2025 -430,964.00
Dec 31, 2024 -85,489.00
Sep 30, 2024 -340,380.00
Jun 30, 2024 105,975.00
Dec 31, 2023 2.65 Mn
Sep 30, 2023 -262,754.00
Jun 30, 2023 -107,933.00